Literature DB >> 9989520

Clinical radiobiology of glottic T1 squamous cell carcinoma.

K Skladowski1, R Tarnawski, B Maciejewski, A Wygoda, K Slosarek.   

Abstract

PURPOSE: Radiation therapy is the treatment of choice for early glottic squamous cell cancer in many institutions over the world. Despite a relatively homogenous clinical model of T1 glottic tumors for the fractionation studies, the relationships between dose-time parameters remain unclear. To analyze the influence of fractionation parameters and hemoglobin level on tumor cure, this study has been performed.
MATERIALS AND METHODS: This is a retrospective review of 235 patients with T1N0M0 glottic cancer treated by radiation therapy alone given in a conventional schedule with 5 fractions each week. The individual total dose, dose per fraction, and overall treatment time (OTT) ranged from 51-70 Gy, 1.5-3.0 Gy, and 24-79 days, respectively. The median follow-up was 48 months. Patient data--total dose, dose per fraction, OTT, and hemoglobin level (Hb) measured before the radiation treatment--were fitted by the mixed LQ/log-logistic model.
RESULTS: The 5-year local relapse-free survival rate was 84%. All parameters included in the mixed LQ/log-logistic model improved the fit significantly. The dose-response curve for 235 patients with T1 glottic cancer was well defined and steep, and showed significant decrease in tumor control probability (TCP) when total doses were below 61 Gy. The 10-day prolongation of OTT, from 45 to 55 days, decreased the TCP by 13%. The dose of 0.35 Gy/day, compensated repopulation during the 1 day of prolongation, which indicates a potential doubling time (Tpot) for glottic T1 tumor clonogens of 5.5 days. The drop of Hb level of 1 g/dl (from 13.8 g/dl to 12.8 g/dl) gave a 6% decrease of TCP, provided that OTT was 45 days.
CONCLUSION: The significant correlation between the total dose, overall treatment time, hemoglobin concentration, and tumor control probability has been found for T1 glottic cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989520     DOI: 10.1016/s0360-3016(98)00375-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  Impact of anemia in patients with head and neck cancer treated with radiation therapy.

Authors:  Kenneth Hu; Louis B Harrison
Journal:  Curr Treat Options Oncol       Date:  2005-01

2.  Outcome of radiotherapy in T1 glottic carcinoma: a population-based study.

Authors:  Elisabeth Victoria Sjögren; Ruud G J Wiggenraad; Saskia Le Cessie; Simone Snijder; Jaqueline Pomp; Robert Jan Baatenburg de Jong
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-10-07       Impact factor: 2.503

3.  Hypofractionated accelerated radiotherapy in T1-3 N0 cancer of the larynx: A prospective cohort study with historical controls.

Authors:  Zbigniew Szutkowski; Andrzej Kawecki; Andrzej Jarząbski; Zofia Laskus; Romuald Krajewski; Wojciech Michalski; Paweł Kukołowicz
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-20

Review 4.  3D conformal hypofractionated radical radiotherapy in early glottic cancer.

Authors:  Ana Cristina Amado; Laurentiu Bujor; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-05-30

5.  Multidisciplinary approach in the treatment of T1 glottic cancer. The role of patient preference in a homogenous patient population.

Authors:  Nicola Dinapoli; Claudio Parrilla; Jacopo Galli; Rosa Autorino; Francesco Miccichè; Francesco Bussu; Mario Balducci; Lucia D'Alatri; Raffaella Marchese; Mario Rigante; Giuseppe Di Lella; Luca Liberati; Giovanni Almadori; Gaetano Paludetti; Vincenzo Valentini
Journal:  Strahlenther Onkol       Date:  2010-11-08       Impact factor: 3.621

Review 6.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature.

Authors:  José A González Ferreira; Javier Jaén Olasolo; Ignacio Azinovic; Branislav Jeremic
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-04

7.  Functional organ preservation in laryngeal and hypopharyngeal cancer.

Authors:  Petra Ambrosch; Asita Fazel
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-04-26

8.  Evaluation of acute/late toxicity and local recurrence in T1-T2 glottic carcinoma treated with accelerated hypofractionated 3D-conformal external beam radiotherapy (3D-CRT).

Authors:  Vassilis E Kouloulias; Anna Zygogianni; Eftychia Mosa; Kalliopi Platoni; John Georgakopoulos; Christos Antypas; Ivelina Beli; Maria Tolia; Paulos Maragoudakis; Ioannis Giotakis; Zisis Papas; Amanda Psyrri; Nikolaos Kelekis; John Kouvaris
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991

9.  Impact and relationship of anterior commissure and time-dose factor on the local control of T1N0 glottic cancer treated by 6 MV photons.

Authors:  Chi-Chung Tong; Kwok-Hung Au; Roger K C Ngan; Sin-Ming Chow; Foon-Yiu Cheung; Yiu-Tung Fu; Joseph S K Au; Stephen C K Law
Journal:  Radiat Oncol       Date:  2011-05-21       Impact factor: 3.481

10.  Short treatment time and excellent treatment outcome in accelerated hyperfractionated radiotherapy for T1 glottic cancer.

Authors:  Yukihisa Tamaki; Yoko Hieda; Rika Yoshida; Takeshi Yoshizako; Takafumi Fuchiwaki; Noriaki Aoi; Kazumasa Sekihara; Kazuhiro Kitajima; Hideyuki Kawauchi; Hajime Kitagaki; Ryohei Sasaki; Taisuke Inomata
Journal:  Nagoya J Med Sci       Date:  2015-11       Impact factor: 1.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.